Over the years, there is an increase in the prescribing of antipsychotics among elderly patients, and these are used for various clinical indications such as psychotic disorders, affective disorders, behavioural and psychological symptoms of dementia and delirium. Suspicion of neuroleptic malignant syndrome (NMS) is a frequent cause of emergent psychiatric consultation. We are reporting a case involving a 48yrs female patient had bipolar disorder and hypertension; she treated with neuroleptic drugs and lithium since 20years. Now she again came with the complaints of altered sensorium, generalized weakness, muscle rigidity, forgetfulness and cough. Finally diagnosed as Neuroleptic malignant syndrome (NMS). NMS is characterized by altered sensorium, generalized weakness, muscle rigidity, and an elevated creatine kinase level. This condition develops after a sudden increase in the dosage of the Neuroleptic medications and Lithium Toxicity. Treatment is mainly withdrawing of neuroleptic medications and supportive measures and possibly administration of bromocriptine, Amantadine, Antibiotics, corticosteroids, vasopressors and vitamin supplements. Complications of NMS include acute kidney failure and acute respiratory failure. Given the widespread prescription by physicians in a variety of fields. All physicians need to be able to recognize and appropriate management for NMS.

Keywords: Neuroleptic Malignant Syndrome, Antipsychotic drugs, Lithium, Neuroleptic drugs, Antidepressants, Hyperthermia, Autonomic dysfunction.

1. Brian D. Berman Neuroleptic Malignant Syndrome: A Review for Neurohospitalists. Journals Permissions, 2011. DOI: 10.1177/1941875210386491
2. M Unaldi, MB Sayhan, O Sogüt, R Demirhan, B Güzel, Neuroleptic malignant syndrome after the addition of lithium to risperidone treatment: a case report and review of the literature. HongKong journal of emergency medicine. Vol. 17(3) .Jul 2010
3. Ustündag M, Orak M, Güloglu C, Sayhan MB, Mahmut Tas M. A case of neuroleptic malignant syndrome induced by olanzapine in postpartum period. Indian J Psychiatry 2007; 49:287-9.
4. Duangjai Kasantikul *, Buranee Kanchanatawan, Neuroleptic Malignant Syndrome: A Review and Report of Six Cases. J Med Assoc Thai 2006; 89 (12): 2155-60.
5. Yanfen YANG, Yahui GUO, Aiguo ZHANG, Neuroleptic malignant syndrome in a patient treated with lithium carbonate and haloperidol. Shanghai Arch Psychiatry. 2014; 26(6): 368-370.
6. Geethan J. Chandran. Neuroleptic malignant syndrome: case report and discussion JAMC, SEPT. 2, 2003; 169 (5). 439-442.
7. Dua D, Grover S. Neuroleptic malignant syndrome in an elderly with quetiapine: A case report and review of literature. J Geriatr Ment Health 2017; 4:64-68.
8. Deepak HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Hanumanthaiah%20D%5BAuthor%5D&cauthor=true&cauthor_uid=24701071"Hanumanthaiah, Kumar HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/?term=Ramanathan%20K%5BAuthor%5D&cauthor=true&cauthor_uid=24701071"Ramanathan. Olanzepine-induced neuroleptic malignant syndrome in a case of multiple sclerosis. Indian J HYPERLINK "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963204/"CritHYPERLINK "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963204/" Care Med. 2014 Mar; 18(3): 178–180.
9. Martino Belvederi Murri, Argentina Guaglianone. Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis. Drugs R D (2015) 15:45–62.
10. Siddharth Sarkar, Nitin Gupta. Drug Information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association. BJPsych Bullet in 2017. 41. 211-216.

P.Bhavana

Pharm.D, Nirmala College of Pharmacy, Mangalagiri, Guntur -522503

Mobile: 9573318501, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.